Nespecel (AT101)
Phase 2CD19 CAR-T using the company's own h1218 antibody; enrollment in its Korean Phase 2 trial in relapsed or refractory B-cell lymphoma was completed in July 2026, with an interim overall response rate of 94%.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Completed Korean Phase 2 enrollment for its CAR-T and signed an exclusive Korean sales agreement with Chong Kun Dang.
Roles often seen at this stageClinical & PV · Regulatory affairs · Manufacturing & MSAT
Develops cancer antibodies and cell therapies using NEST, its platform for finding antibodies that bind new epitopes, and CAR-T technology.
CD19 CAR-T using the company's own h1218 antibody; enrollment in its Korean Phase 2 trial in relapsed or refractory B-cell lymphoma was completed in July 2026, with an interim overall response rate of 94%.
HER2-targeting antibody; partner Henlius is running a global Phase 3 trial in gastric cancer.
Signed a definitive agreement with Chong Kun Dang for exclusive Korean supply and sales of nespecel; AbClon handles approval, reimbursement and manufacturing, and Chong Kun Dang handles distribution and sales after approval.
Completed patient enrollment in the Korean Phase 2 trial of nespecel.
Completed a 12.2 billion won strategic investment from Chong Kun Dang.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.